TRDA (Entrada Therapeutics) Tariff Resilience Score: 5/10 (As of Jul. 02, 2026)


TRDA Entrada Therapeutics Inc TRDA
23 GF Score
Price $7.59
GF Value $0.95
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Entrada Therapeutics Tariff Resilience Score?

Entrada Therapeutics TRDA +2.99% 23 Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus rates TRDA with a GF Score™ of 23/100 and a GF Value™ of $0.95 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,374 Biotechnology companies, Entrada Therapeutics ranks better than 62.23% on this metric.

Entrada Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Entrada Therapeutics has Entrada Therapeutics relies on global supply chains for drug development. While tariffs can affect raw material costs, its innovative products and potential pricing power provide some buffer against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Entrada Therapeutics might have Average Resilient.

Entrada Therapeutics  (NAS:TRDA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Entrada Therapeutics Tariff Resilience Score Related Terms

TRDA vs NMRA, MGNX, CNXU: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Entrada Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Tariff Resilience Score falls into.


TRDA
23GF Score
Entrada Therapeutics Inc TRDA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Entrada Therapeutics (TRDA) has a Tariff Resilience Score of 5 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Entrada Therapeutics ranks #519 out of 1374 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Entrada Therapeutics' Tariff Resilience Score too high?
Entrada Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Entrada Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Entrada Therapeutics ranks #519 out of 1374 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Entrada Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Tariff Resilience Score compare to NMRA and MGNX?
According to the Biotechnology industry distribution chart, Entrada Therapeutics ranks #519 out of 1374 companies for Tariff Resilience Score. This puts Entrada Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Entrada Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entrada Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entrada Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.95, compared to a current price of $7.59 — trading 698.9% above its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Entrada Therapeutics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Entrada Therapeutics (TRDA) Overvalued in 2026?

Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued. The current stock price of $7.59 is trading 698.9% above its estimated GF Value™ of $0.95. GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.

Key valuation signals for TRDA:

  • Tariff Resilience Score: 5
  • GF Value™: $0.95 vs. price of $7.59 (698.9% above fair value)
  • GF Score™: 23/100 with 4 warning signs
  • Industry Position: 25% above the Biotechnology median (#519 of 1374)

No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entrada Therapeutics Business Description

Address One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
23GF Score

Get the complete analysis for TRDA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.59
Price
$0.95
GF Value